142 related articles for article (PubMed ID: 12356203)
1. Quality of life in multiple sclerosis: influence of interferon-beta1 a (Avonex) treatment.
Vermersch P; de Seze J; Delisse B; Lemaire S; Stojkovic T
Mult Scler; 2002 Oct; 8(5):377-81. PubMed ID: 12356203
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon β-1a in Iran.
Pakdaman H; Amini Harandi A; Gharagozli K; Abbasi M; Tabassi A; Ashrafi F; Ghaffarpor M; Sharifi S; Delavar Kasmae H; Assarzadegan F; Arabahmadi M; Behnam B
Int J Neurosci; 2017 Jun; 127(6):501-507. PubMed ID: 27279451
[TBL] [Abstract][Full Text] [Related]
3. Interferon-beta-1a treatment has a positive effect on quality of life of relapsing-remitting multiple sclerosis: results from a longitudinal study.
Patti F; Pappalardo A; Montanari E; Pesci I; Barletta V; Pozzilli C
J Neurol Sci; 2014 Feb; 337(1-2):180-5. PubMed ID: 24433926
[TBL] [Abstract][Full Text] [Related]
4. Improvement of health-related quality of life in relapsing remitting multiple sclerosis patients after 2 years of treatment with intramuscular interferon-beta-1a.
Jongen PJ; Sindic C; Carton H; Zwanikken C; Lemmens W; Borm G;
J Neurol; 2010 Apr; 257(4):584-9. PubMed ID: 19921303
[TBL] [Abstract][Full Text] [Related]
5. [Open trial of the effectiveness of interferon beta 1a (Avonex) in multiple sclerosis. Clinical assessment using motor coordination tests].
Selmaj K; Członkowska A; Kwieciński H; Losy J; Podemski R; Stelmasiak Z
Neurol Neurochir Pol; 2003; 37(6):1163-83. PubMed ID: 15174231
[TBL] [Abstract][Full Text] [Related]
6. Multiple sclerosis and depression: influence of interferon beta therapy.
Zephir H; De Seze J; Stojkovic T; Delisse B; Ferriby D; Cabaret M; Vermersch P
Mult Scler; 2003 Jun; 9(3):284-8. PubMed ID: 12814176
[TBL] [Abstract][Full Text] [Related]
7. Quality of life during the first 6 months of interferon-beta treatment in patients with MS.
Arnoldus JH; Killestein J; Pfennings LE; Jelles B; Uitdehaag BM; Polman CH
Mult Scler; 2000 Oct; 6(5):338-42. PubMed ID: 11064444
[TBL] [Abstract][Full Text] [Related]
8. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.
Rudick RA; Fisher E; Lee JC; Duda JT; Simon J
Mult Scler; 2000 Dec; 6(6):365-72. PubMed ID: 11212130
[TBL] [Abstract][Full Text] [Related]
9. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
Pokryszko-Dragan A; Bilińska M; Gruszka E; Dubik-Jezierzańska M
Pol Merkur Lekarski; 2005 Nov; 19(113):654-8. PubMed ID: 16498805
[TBL] [Abstract][Full Text] [Related]
10. The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosis.
Cohen JA; Krishnan AV; Goodman AD; Potts J; Wang P; Havrdova E; Polman C; Rudick RA
JAMA Neurol; 2014 Nov; 71(11):1386-93. PubMed ID: 25178496
[TBL] [Abstract][Full Text] [Related]
11. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
12. Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a.
Miller DM; Weinstock-Guttman B; Bourdette D; You X; Foulds P; Rudick RA
Mult Scler; 2011 Jun; 17(6):734-42. PubMed ID: 21300736
[TBL] [Abstract][Full Text] [Related]
13. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
[TBL] [Abstract][Full Text] [Related]
14. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
[TBL] [Abstract][Full Text] [Related]
15. Impact of peginterferon beta-1a and disease factors on quality of life in multiple sclerosis.
Newsome SD; Guo S; Altincatal A; Proskorovsky I; Kinter E; Phillips G; You X; Sabatella G
Mult Scler Relat Disord; 2015 Jul; 4(4):350-7. PubMed ID: 26195056
[TBL] [Abstract][Full Text] [Related]
16. Quality of life in 1000 patients with early relapsing-remitting multiple sclerosis.
Putzki N; Fischer J; Gottwald K; Reifschneider G; Ries S; Siever A; Hoffmann F; Käfferlein W; Kausch U; Liedtke M; Kirchmeier J; Gmünd S; Richter A; Schicklmaier P; Niemczyk G; Wernsdörfer C; Hartung HP;
Eur J Neurol; 2009 Jun; 16(6):713-20. PubMed ID: 19475754
[TBL] [Abstract][Full Text] [Related]
17. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
[TBL] [Abstract][Full Text] [Related]
18. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.
Arroyo González R; Kita M; Crayton H; Havrdova E; Margolin DH; Lake SL; Giovannoni G;
Mult Scler; 2017 Sep; 23(10):1367-1376. PubMed ID: 27885061
[TBL] [Abstract][Full Text] [Related]
19. Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment.
Lily O; McFadden E; Hensor E; Johnson M; Ford H
Mult Scler; 2006 Dec; 12(6):808-13. PubMed ID: 17263011
[TBL] [Abstract][Full Text] [Related]
20. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
Shirani A; Zhao Y; Karim ME; Evans C; Kingwell E; van der Kop ML; Oger J; Gustafson P; Petkau J; Tremlett H
JAMA; 2012 Jul; 308(3):247-56. PubMed ID: 22797642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
